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Abstract
Background: Sub-clinical variant Creutzfeldt-Jakob disease (vCJD) infection and reports of vCJD
transmission through blood transfusion emphasise the need for blood screening assays to ensure
the safety of blood and transplanted tissues. Most assays aim to detect abnormal prion protein
(PrPSc), although achieving required sensitivity is a challenge.
Methods: We have used innovative Atomic Dielectric Resonance Spectroscopy (ADRS), which
determines dielectric properties of materials which are established by reflectivity and penetration
of radio/micro waves, to analyse blood samples from patients and controls to identify characteristic
ADR signatures unique to blood from vCJD and to sCJD patients. Initial sets of blood samples from
vCJD, sCJD, non-CJD neurological diseases and normal healthy adults (blood donors) were
screened as training samples to determine group-specific ADR characteristics, and provided a basis
for classification of blinded sets of samples.
Results:  Blood sample groups from vCJD, sCJD, non-CJD neurological diseases and normal
healthy adults (blood donors) screened by ADRS were classified with 100% specificity and
sensitivity, discriminating these by a co-variance expert analysis system.
Conclusion: ADRS appears capable of recognising and discriminating serum samples from vCJD,
sCJD, non-CJD neurological diseases, and normal healthy adults, and might be developed to
provide a system for primary screening or confirmatory assay complementary to other screening
systems.
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Background
The human prion diseases or transmissible spongiform
encephalopathies (TSEs) are a group of fatal neurodegen-
erative disorders believed to be caused by a post-transla-
tional conformational change in cellular prion protein
from its soluble form (PrPC) to a pathogenic protease
resistant isoform PrPSc [1]. The most common of these is
sporadic Creutzfeldt-Jakob disease (sCJD) but a variant
form of CJD (vCJD) was identified in the UK in 1996 [2]
and has been linked to human infection by the bovine
spongiform encephalopathy (BSE) agent. Existing clinical
tests for Creutzfeldt-Jakob disease (CJD) can establish a
diagnosis of probable variant or probable sporadic CJD
during the clinical phase of disease, but a definitive diag-
nosis depends on post-mortem examination of the brain.
Moreover there is currently no practical way of determin-
ing whether an individual who is not manifesting symp-
toms is incubating the disease.
The presence of PrPSc in the peripheral tissues of patients
with vCJD [3,4] and experimental transmissions of BSE
and natural scrapie between sheep by blood transfusion
[5,6] raised the possibility that iatrogenic transmission in
humans by blood transfusion could occur. This risk has
unfortunately been confirmed by recent reports of trans-
mission of vCJD by blood transfusion [7-10]. The annual
number of deaths from variant CJD has been declining
since a first peak in 2000. However, the prevalence of
infected individuals in the general UK population, as
judged by a retrospective tonsil and appendix tissue study,
appears to be higher than would be expected from the
mortality rates, pointing to substantial numbers of sub-
clinically infected individuals in the general population
[11,12]. To date all reported clinical cases of vCJD have
been homozygous for methionine at codon 129 of the
prion protein gene (PRNP), and there has been uncer-
tainty over the susceptibility of the heterozygous and
valine homozygous genetic sub-groups. There are now
good reasons to believe that all PRNP codon 129 geno-
typic groups are susceptible to infection [9,13] and it is
possible that heterozygous and valine homozygous indi-
viduals may exhibit prolonged incubation periods or
might remain in a sub-clinical state throughout life. In the
absence of a screening test for vCJD these individuals
could be a major source of iatrogenic transmission. Cur-
rent methods that might identify these pre- or sub-clinical
individuals, such as lymphoreticular biopsy, are highly
invasive and clearly impractical as screening measures for
blood donations. A screening assay that could be applied
to a routine blood sample is urgently required.
Although there is a presumption that PrPSc is the infec-
tious agent, the association of infectivity with blood is
poorly understood. There is growing evidence from stud-
ies in mice and hamsters that initial TSE replication occurs
in lymphoreticular tissues [14,15] prior to invasion of the
central nervous system (CNS) via the sympathetic nervous
system [16-19]. Recent reports of the transmission of nat-
ural scrapie and experimental BSE between sheep by
whole blood and buffy coat transfusion support the the-
ory that infectivity is associated with, but not restricted to,
the white cell component [20]. Given that levels of detect-
able PrPSc and infectivity in peripheral lymphoreticular
tissues such as spleen and tonsil in patients with vCJD are
2–3 logs lower than levels detected in the CNS [4,21], it is
likely that PrPSc is present at very low concentrations in
peripheral blood. Attempts to detect PrPSc in human buffy
coat by Western blot have thus far proven unsuccessful
[4]. Intracerebral inoculation of human buffy coat from
clinical vCJD cases into susceptible mouse models has
also failed to demonstrate infectivity [22], although this
could be a reflection of species barrier and/or the small
numbers of animals used in addition to the limited vol-
ume of inoculum that can be delivered intracerebrally.
Because of its evident very low level, pre-mortem tests
designed for the detection of any PrPSc present in blood/
body fluids would require a high level of sensitivity, prob-
ably several logs greater than those diagnostic tests already
approved by the European Commission and in place for
post mortem TSE disease confirmation in slaughterhouse
cattle and sheep. Many of these tests rely upon proteolytic
treatments to digest PrPC and may lack the sensitivity
required for blood screening as they may remove protease
sensitive isoforms of disease associated prion protein.
There are a number of emerging diagnostic tests in devel-
opment for pre-mortem diagnosis which may possibly be
capable of detecting PrPSc in peripheral blood, amongst
which the protein misfolding cyclic amplification
(PMCA) appears particularly promising [23,24], but none
of these has yet been validated in extensive study of
human blood samples. These have recently been reviewed
by Brown [25].
The difficulties of achieving the sensitivity needed for the
detection of PrPSc has shifted efforts to an alternative
approach of screening for biomarkers other than prion
protein. Potential candidates assays have been recently
reviewed by Parveen et al. [26]. However most lack the
specificity and sensitivity to be useful as diagnostic screen-
ing tests and would need to be employed with an array of
confirmatory assays. At present many do not have data on
studies of CJD in humans. Despite this there exist a small
number of promising alternate approaches. Amongst
these, emerging spectroscopic methods, for example the
use of Fourier transform infrared spectroscopy (FT-IR) as
a test for BSE in cattle or preclinical scrapie in hamsters,
have been described [27,28]. Analysis of blood serum by
FT-IR supported by artificial neural network or multivari-
able pattern recognition analysis allowed the sensitive
and specific discrimination between healthy and infectedJournal of Translational Medicine 2007, 5:41 http://www.translational-medicine.com/content/5/1/41
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animals [28,29]. In this paper we report on the develop-
ment and assessment of atomic dielectric resonance
(ADR) spectroscopic techniques in an analysis of clinical
blood samples from patients with CJD. This also employs
Fourier transformation and complex pattern analysis.
ADR is a new technology exploiting novel properties of
resonance of radio waves from X-band and C-band radar
developed for aerospace and ground remote sensing,
imaging, and materials detection and recognition through
surface boundaries. This technology has been recently
described in a patent [30]. ADR spectroscopy (ADRS)
exploits dielectric properties of materials which determine
reflectivity and penetration of radio/micro waves, allow-
ing the use of electromagnetic energy as a means of
remotely detecting and measuring target characteristics.
Different materials have unique energy absorption and
reflection properties and provide spectra in the broad
range of frequencies employed that provide signatures for
materials recognition and matching (typecasting). ADRS
has been developed for a broad range of applications pre-
dominantly in geophysical, engineering or security fields
which have not been published because of commercial or
other sensitivities. Several small scale biological labora-
tory or clinical (patient or tissue) studies have indicated
potential utility of ADR in biomedical investigation both
in subsurface imaging and in materials characterisation,
and the apparatus has been approved as a medical device
for use in human subject studies as well as in the labora-
tory. However, interest in application of ADR in this area
is novel and as yet no formal studies in a biomedical con-
text have been published. ADR employs very low energy
emission, and is a reagent free non-destructive non-con-
suming test. Unlike infrared spectroscopy, there is no
requirement for drying or other special treatment of test
materials. Preliminary (unpublished) studies by us of his-
tology slides (remaining from a separate histology study)
of brain sections from experimental scrapie infected mice
and uninfected controls illustrated that it was possible to
clearly distinguish scrapie infected mice at a range of
stages of scrapie infection from normal controls by match
ranking of ADR spectra taken from these slides [31].
Results are presented here which demonstrate how char-
acteristic ADR signatures can be exploited to discriminate
between the blood of patients with clinical sCJD, those
with clinical vCJD, those from non-CJD neurological con-
trol patients and those from healthy adult (blood donor)
controls.
Methods
Collection of blood samples
Anonymised whole-blood samples from healthy adult
donors were collected by the Scottish National Blood
Transfusion Service Edinburgh and stored for 24 hours at
4°C to mimic the conditions of collection of samples
from CJD patients transported to the National CJD Sur-
veillance Unit in Edinburgh from around the UK. Blood
from CJD patients and neurological controls were
obtained by the National CJD Surveillance Unit primarily
for genetic analysis: however consent was obtained for
research use of any remaining specimen. Whole blood
samples from vCJD, sCJD patients, and neurological con-
trols were used in ADRS studies. Informed consent was
also obtained from donors for experimentation. All vCJD
and sCJD cases had a probable or definitive diagnosis
based on internationally established criteria [32,33]. The
neurological control group were samples from patients
referred to the CJD Surveillance Unit who subsequently
did not meet criteria for a diagnosis of definite or proba-
ble CJD and who can be assumed to be suffering from
neurological diseases other than CJD or other prion disor-
ders. Whole blood samples were handled, separated, and
stored in an identical manner to ensure groups were
directly comparable in scientific investigations. Samples
were collected into 9 mL vacuettes containing 1 mL of
3.2% tri-sodium citrate (Greiner Bio-One, Ltd, Glouces-
tershire, UK).
ADRS apparatus and sampling
The ADRS hardware for this study consisted of a radio-
wave sampling control unit (RCU), a pulse generator (PG)
and a Test Sample Chamber (TSC) in which individual
samples were placed which incorporated a transmitting
and receiving antenna array. Resonant scan-returns were
received from the illuminated samples in their containers
in a 90 degree cross polarised mode and then transferred
directly to a PC where the image data were digitally stored.
Samples (500 µL) were dispensed into the same batch of
2 mL polypropylene tubes with caps and placed onto a
spot within the sample chamber. Four scans of each sam-
ple were taken. Scans were also taken on empty tubes for
subtraction of spectra. As far as we could ensure, no arte-
facts were introduced from any differences in handling,
storage, or dispensing of samples. Sample codes for each
sample were recorded with spectral data and stored in the
linked data acquisition computer.
Samples were pulsed with radar in the spectral range 0–
25000 MHz and spectral frequency and energy measure-
ments (images) were classified using energy bins. The
image data were first subjected to fast Fourier transform
(FFT) analysis using the RADAMATIC software, proprie-
tary software developed by Radar World Ltd, which is
optimised for analysing the Atomic Dielectric Resonance
behaviour of materials when subjected to a coherent
beam of lased invisible light photons. The bandwidth of
the pulsed transmit (Tx) energy was 1 GHz but the ADR
spectral responses were analysed from the received (Rx)Journal of Translational Medicine 2007, 5:41 http://www.translational-medicine.com/content/5/1/41
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digital signals by FFT methods using 1024 point samples
in each case from 100 MHz to 51.2 GHz.
First Study design
Whole blood samples from 5 different patients or blood
donors for each of vCJD, sCJD, neurological controls and
healthy adult blood donor control groups were assembled
for testing in unlabelled 2 ml polypropylene tubes. Of
these 2/5 were left un-blinded and used as controls for
training, leaving the remaining 3/5 samples as blinded
test samples which were randomised. Clinical and control
sample groups were assigned alphabetic codes to ease data
analysis, vCJD: A; sCJD: B; Neurological controls: C;
Healthy blood donor controls: D, E.
Primary analysis of ADR spectra
The FFT generated spectral data sets for clinical and con-
trol samples were analysed using RADAMATIC ADR and
Image Analysis software developed and owned by Radar
World Ltd. In classic EM Theory, the EM properties of the
mediums of propagation (air, water, soil, rock and biolog-
ical materials, for example) there are three key variables
which are usually studied:
(1) Dielectric permittivity (ε)
(2) Magnetic permeability (µ), and
(3) Electric conductivity (σ)
The mathematical and statistical methods of ADR analysis
produce synthetic relationships which can then be used to
compute very precise values of ε, µ and σ. The software
analysis incorporated is primarily concerned with identi-
fying materials which have to be mapped or assessed in
some way. If change detection is important, then the soft-
ware is concerned with mapping the extent or spread of
the material in question over specific time scales to mon-
itor increased or decreased spatial or volume extents. In
order to unambiguously identify the material in question
the software does not necessarily need to know the spe-
cific values of ε, µ and σ, which, per se, may not necessarily
identify the unknown material in question, but it may be
necessary to establish 10 or 12 other mathematical or sta-
tistical relationships related to the energy-frequency spec-
tra of the unknown material in question, to establish from
the ADR control database of such parameters unquestion-
ably what the material's code is by the software's logical
expert systems method of discrimination.
Primary data analysis consisted of the subtraction of ADR
image data generated by scanning the empty tube from
ADR spectral image data generated by each test sample.
The resultant data represented true ADR image data for
blood samples alone, with no contribution from the sam-
ple tube. These data were then re-compiled into an ADR
spectral data base where rank matching of the 10 or 12
established spectral relationships were tested for within
group and between group relationships. An expert system
was developed using the control logic results of the anal-
ysis of variance tables and this finally was able to identify
the unique code attributed to each sample tested. The
final results were proved to be 100% correct on two sepa-
rate occasions when double blind test procedures were
adopted. It is important to add that 100% accuracy is only
achieved in identifying new materials by this method pro-
vided that a set of at least 20% control samples are
"trained" by this ADR spectroscopic method and the logic
control relationships are mathematically defined from
this result for the Expert Systems Analysis Method which
is used to identify the unknown (blinded) samples.
Match Ranking Analysis
In an attempt to identify blinded samples, unprocessed
Fourier transformed ADR spectra were match ranked. This
method employed a single scan of a known training sam-
ple used as a reference spectrum against which the remain-
ing scans of control and test samples were matched. The
closeness of the matching was based upon determining
the correlation coefficient values and setting them in
order, therefore the closer to 1 or in this case 100% the
more exact the match. It was considered that this
approach may allow classification of blinded samples by
measuring their level of correlation to a known reference
sample.
Analysis of variance classification: Expert systems analysis
An expert system was developed based upon analysis of
variance of frequency data within groups and between
groups. Studying firstly the similarities, and then the dif-
ferences between different samples groups produced a
series of relationships which were used to develop logic
relationships and an expert system. The identification of
robust sets of P-value relationships for each sample group
allowed the classification of test samples. The P-ratios of
variance between and within groups were calculated by
rank and cluster analysis of ADR-ratio data using Rada-
matic software.
Second Study design
To validate the ability of expert systems analysis methods
to correctly identify and distinguish between clinical CJD
and control samples a second study was undertaken. 10
whole blood samples were obtained from the National
CJD Surveillance Unit frozen archives. All samples were
blinded and included 4 vCJD, 3 sCJD, and 3 samples from
non-CJD neurological controls. It was ensured that none
of the samples had been included in the first ADR spec-
troscopy study. Thawed whole blood samples (0.5 ml) in
2 ml storage tubes were scanned 4 times and scans of anJournal of Translational Medicine 2007, 5:41 http://www.translational-medicine.com/content/5/1/41
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empty storage tube were subtracted from sample scans so
that spectral data represented the blood sample alone.
Spectral data from this study was classified using the data
obtained in the first study.
Results
First study
In the first study ADRS spectra from 4 scans each were
obtained from whole blood samples from clinical
patients with sCJD and vCJD and healthy adult donors
and neurological control patients. The first study was
essentially used for system evaluation and training pur-
poses, to an extent to determine how much training of the
system on known samples was required for unambiguous
discrimination of the remaining samples, and which anal-
ysis procedures could achieve this. Spectra were analysed
by combinations of analysis techniques to assess the best
classification methods. For primary analysis spectral data
was compiled into tables which show ADR parameters
(F1, F2) between 1–99% energy bins and the ADR ratio
which is a measure of the rate of change of resonance with
frequency cut-off per energy bin. There are a number of
important observations which can be made from studying
the data presented in Table 1 which summarizes the first
20% E-bin results and the last 10% E-bin results for indi-
vidual samples from the vCJD and the sCJD sample
groups from the detailed fast Fourier transform (FFT)
tables computed by the Radamatic software. At the 99%
energy level the frequency resonance is 947 MHz for vCJD
compared with 1320 MHz for sCJD. However the actual
resonance value at this level as computed by the standard
variance f2 ADR parameter statistic is much higher (+/-
32.3 MHz) for vCJD than that (+/-13.6 MHz) for sCJD.
This is a significant result, which can be summarized in
the ADR-Ratio. This is an inverse index and the lower the
ADR-Ratio the higher the ADR parameter. In this case
vCJD yields an ADR-ratio of 29.348 at the 99% energy-bin
compared with 97.216 for sCJD. There is also a distinct
trend of resonance variability with vCJD compared with
sCJD. For the 1st 7 energy-bins the ADR-ratio for sCJD is
constant at 15.7, whereas the ADR-ratios for vCJD vary
considerably from 4 (1%), 11 (2%), 31 (3%), 49 (4%), 32
(5%), 21 (6%) and 15 (7%).
To highlight spectral differences between samples, the
amplitude (or maximum wave displacement of absorp-
tion spectra) of the same vCJD and sCJD samples were
plotted against energy in decibels (Db). Figure 1 shows
the FFT difference plot created by subtracting the vCJD
spectral data from the sCJD spectral data. This illustrates
the variability of vCJD over sCJD, particularly from 3000
MHz to 25000 MHz and could be a useful diagnostic indi-
cator of differences between groups. The spectral detail
represents all molecular groups contained in the whole
blood sample, and it is not possible at this time to assign
spectral signals to specific molecular constituents of the
blood. It is not apparent at this stage of the analysis
whether these interesting spectral differences between
individual samples are associated with the clinical class of
the samples. They may merely reflect differences such as
blood type between individuals and factors which are not
associated with disease status. A detailed analysis of much
larger sample numbers from each clinical class may per-
mit the identification of particular spectral patterns able
to rapidly distinguish vCJD from sCJD or from healthy
adult blood samples, without the need for complex anal-
ysis.
Relatively simple match ranking data analysis techniques,
based on correlation, were used first to analyze ADR spec-
tra to identify unknown samples by studying the correla-
tion coefficient values when matched against the reference
spectrum of a single known training sample. There was
discrete clustering of a large proportion of samples
according to class, which indicated strong clinical features
of many samples which dominated over the individuality
of control samples. Clinical and control samples segre-
gated at opposite ends of the range which infers the pres-
ence of a unique combination of physiological factors
which distinguish them. However, segregation of clinical
and control groups was not absolutely discrete and did
FFT Difference plot comparing vCJD spectra with sCJD spec- tra Figure 1
FFT Difference plot comparing vCJD spectra with 
sCJD spectra. Illustrates the FFT Difference plot by sub-
tracting an individual vCJD spectra from an individual sCJD 
spectra. This shows the variability of vCJD over sCJD, partic-
ularly from 3000 MHz to 25000 MHz and is again a useful 
diagnostic indicator of differences.Journal of Translational Medicine 2007, 5:41 http://www.translational-medicine.com/content/5/1/41
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not improve the ability to identify unknown samples with
confidence. Additional strategies for primary analysis
including filtering spectral data and image analysis were
tried to identify blinded samples, but it became evident
that match ranking was not sufficiently reliable to detect
the identity of all samples. At this stage the identities of all
clinical and control samples in the first study were un-
blinded to allow the entire data set to be used to develop
expert system analysis algorithms for identification of the
classes of clinical and control whole blood samples.
To develop the expert system the 4 scans each of the first
training sample from each clinical and control sample
class were used to compute P-value tables, producing a
series of 13 parameters to define each sample group. Each
parameter produced a series of defining statistics and rela-
tionships between sample classes, the summation of
which led to the development of an expert system of anal-
ysis able to characterise the different sample classes. A P-
value computation to produce revised parameters enabled
the correct classification of all previously blinded samples
with 100% specificity and accuracy. Due to sample varia-
bility between patients the identification of the class of
20% of all samples was necessary for adequate training to
ensure correct classification of the remaining 80% of sam-
ples at the 0.001% significance level or 0.05% confidence
level.
Second study
To validate the P-value co-variance expert system a small
second blinded study of clinical and neurological control
whole blood samples was undertaken. Spectral data was
handled as for the first study. Frequency analysis of ADR
spectra produced ADR-ratio data, and rank and cluster
Table 1: ADR parameters for individual vCJD and sCJD samples from the first study
E(%) f1(MHz) f2(MHz) ADR-Ratio
vCJD sCJD vCJD sCJD vCJD sCJD
11 8 6 . 0 22.0 42.0 1.4 4.412 15.700
22 1 2 . 0 45.0 17.8 2.9 11.939 15.700
32 3 0 . 0 67.0 7.4 4.3 31.063 15.700
42 4 8 . 0 90.0 5.0 5.7 49.842 15.700
52 6 6 . 0 112.0 8.1 7.1 32.733 15.700
62 8 4 . 0 134.0 13.4 8.6 21.246 15.700
73 0 2 . 0 157.0 19.1 10.0 15.858 15.700
83 2 1 . 0 179.0 24.2 11.0 13.264 16.292
93 3 9 . 0 199.0 25.6 10.2 13.229 19.478
10 357.0 214.0 24.0 10.9 14.851 19.674
11 375.0 229.0 20.4 11.0 18.373 18.048
12 391.0 245.0 15.6 14.7 25.022 16.605
13 394.0 260.0 10.9 16.9 36.211 15.393
14 397.0 275.0 7.4 19.1 53.853 14.390
15 400.0 290.0 6.0 21.4 66.388 13.559
16 403.0 305.0 6.1 23.7 66.204 12.866
17 406.0 320.0 6.1 25.9 66.019 12.351
18 409.0 335.0 6.2 26.7 65.832 12.516
19 412.0 350.0 6.3 27.1 65.644 12.887
20 415.0 365.0 6.3 27.2 65.456 13.394
90 717.0 904.0 22.5 6.1 31.810 147.013
91 727.0 915.0 21.8 5.6 33.446 162.748
92 738.0 927.0 22.3 5.1 33.075 181.498
93 748.0 938.0 24.1 4.6 31.050 204.118
94 759.0 950.0 28.2 4.1 26.890 231.745
95 769.0 961.0 34.6 3.6 22.233 265.856
96 780.0 973.0 42.9 5.6 18.170 174.787
97 832.0 54.0 51.2 26.7 16.253 39.452
98 889.0 173.0 48.0 22.1 18.539 53.040
99 947.0 1320.0 32.3 13.6 29.348 97.216
Data shown are the ADR parameters f1 and f2 and the ADR-ratio for individual vCJD and sCJD samples for energy levels E-bin 1% to E-bin 20%, 
and E-bin 90% to E-bin 99%.Journal of Translational Medicine 2007, 5:41 http://www.translational-medicine.com/content/5/1/41
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analysis using Radamatic software was used to produce P-
ratios of variance which produced a range of indices used
as discreet classifiers for the unknown samples. The P-var-
iance data classification parameters defined by training
the system with samples in the first study were used to cor-
rectly identify the blinded samples in this subsequent
study by studying the percentage correlation of oscillation
between the unknown sample and the classification
parameters which define each clinical and control group.
These unknown samples were identified with 100% spe-
cificity and accuracy.
Discussion
We have presented proof of principle of a potential
method employing ADR spectroscopy and an expert sys-
tems statistical spectral analysis for the classification of
sCJD and vCJD clinical and neurological control and
healthy adult whole blood samples. This classification
system was developed in an initial study and validated by
a subsequent small blind study where samples were cor-
rectly identified with 100% sensitivity and specificity. The
findings suggest that there are distinct physiological mark-
ers detectable in clinical whole blood samples from vCJD
and sCJD patients by ADR spectroscopy. These methods
present a rapid, non-destructive reagent-free test system
for the clinical diagnosis of patients with CJD that is not
(knowingly) dependent on the detection of PrPSc for their
classification. The number of samples analysed in these
studies is small. Nevertheless the probability that these
could be discriminated with 100% specificity and sensitiv-
ity by chance is extremely low. A much larger validation
study of healthy adult controls, clinical CJD, non-CJD
control samples, along with samples from patients with a
wide spectrum of neurological, infectious and non-infec-
tious conditions is required to assess to what extent the
expert system statistical parameters are specific for each
group or whether the spectral structural compositional
alterations characteristic in CJD blood samples are shared
by other neurological and infectious diseases.
ADR spectral analysis reveals that there are distinct struc-
tural compositional features being detected in clinical
CJD blood samples. As for FT-IR studies which have dis-
criminated TSE infection in sera from different species
[34], the exact nature of the ADR spectral alterations is
unknown. They are more likely to be due to distinct com-
binations of blood physiological features for particular
disease classes rather than due to the detection of low lev-
els of PrPSc. Detection of PrPSc was the assumption in a
preliminary (unpublished) mouse scrapie study where
PrPSc in brain tissue is prevalent, and where correlation-
based match ranking was sufficient to discriminate
between normal mouse brain (which included some cases
of non-scrapie pathological abnormalities), and mouse
brain from a range of stages of scrapie infection [31].
ADRS is a new technology and while it is excellent at rec-
ognising materials by comparison to databases it can not
yet assign spectral features to specific molecular entities as
may be possible for some interpretations of FT-IR [34].
The advantage that ADRS may have over FT-IR even at this
early stage of development is that there are no special
requirements for sample preparation such as drying, and
that a very wide spectral frequency range is used which
provides more possibilities for discriminatory analysis.
Indirect improvements in sensitivity may be possible. For
example, the system might be trained to recognise and
cancel out intrinsic differences associated with different
blood types in test samples, so as to increase the reliability
of the system analysis for CJD diagnosis. It may also be
possible to simplify methods by separating blood into
constituent components and determining whether some
component is more strongly associated with the ability to
be discriminated by ADRS. For example, CJD plasma sam-
ples might be more easily identified if the spectral noise of
blood samples is reduced by removing cells and cell
debris if these do not contribute to the spectral discrimi-
nation. Investigations of pre-clinical blood samples from
experimental TSE animal models and from individuals
known to have received infected blood, if available,
would also be important in the development of a pre-
mortem screening test using ADR spectroscopy. At this
stage, the analysis of data is greatly dependent on the
expertise and intuition of the developers of ADRS at Radar
World Ltd. However, when the analysis parameters are
fully validated and assessed in extended studies, and if
necessary improved, the analytical algorithms can be
incorporated into hardware or software which can be
employed by inexperienced users in specific applications.
The ADRS method described here presents a unique
approach for the diagnosis of CJD using blood, and it is
possible that with further study these methods may be
adapted for the screening of donated blood for vCJD in
the pre- or sub-clinical phase to ensure the removal of
infected blood components from the supply chain and
consequently a reduction in the risk of iatrogenic trans-
mission of vCJD. In effect, this could restore access to
blood donor populations currently proscribed in the UK,
such as those who have previously received blood transfu-
sion or blood products, and restore access to UK blood
donor plasma for its fractionation into blood products. If
other tests suitable for screening blood samples for CJD
are developed, they are likely to be based on different
technologies. An ADRS-based test would represent a com-
plementary partner for such a test in screening systems
where one could be employed as the primary screening
system and the other as a validation system. Speculatively,
it is also possible that since ADRS is very low energy and
suitable for use as a medical device, and conformations ofJournal of Translational Medicine 2007, 5:41 http://www.translational-medicine.com/content/5/1/41
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ADRS hardware can be developed for non-invasive patient
scanning to produce images and spectra from tissue
within the patient, ADRS could be developed and systems
trained to identify tissues affected by TSE disease. Such a
development might be capable of detecting deposition of
PrPSc in lymphoid and other tissue in vCJD infection,
since we know from preliminary studies in scrapie
infected mouse brain that PrPSc has a strong dielectric sig-
nal in ADRS, and which would also be a valuable contri-
bution to identifying subclinical vCJD infection.
Conclusion
We have established in a proof of concept study that
ADRS can discriminate between blood samples from
patients with clinical vCJD, sCJD, non-CJD neurological
diseases and from normal healthy adults with 100% sen-
sitivity and specificity. A larger validation is now required
to assess the specificity of the expert system statistical
parameters for CJD blood samples compared to a wide
range of other neurological and infectious diseases. Fur-
ther studies are required to investigate whether ADRS
could be used to recognise pre- or sub-clinical vCJD cases,
with a view to determining whether ADRS could be devel-
oped as a blood screening system.
Competing interests
The authors declare that they have no competing interests.
Rader World Ltd participated on a voluntary basis out of
scientific curiosity and is not currently developing a com-
mercial interest in this field.
Authors' contributions
GRB and GCS conceived of the study, and participated in
its design with TJF and MWH. JWI and MLT authorized
access to patient and blood donor samples for the study
and contributed clinical expertise and oversight to the
study design and critical comment on the results. TJF pre-
pared all samples and participated in their screening with
GCS and MJR. Data was analysed by GCS, MJR and GS in
liaison with TJF and GRB. TJF and GRB drafted the manu-
script and all authors read and approved the final manu-
script.
Acknowledgements
We acknowledge the support of patients and families affected by vCJD and 
sCJD for consenting to provide blood samples for these studies. We also 
thank apheresis blood donors and staff at the Scottish National Blood 
Transfusion Service for making control samples available.
References
1. Prusiner SB: Novel proteinaceous infectious particles cause
scrapie.  Science 1982, 216:136-144.
2. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alpero-
vitch A, Poser S, Pocchiari M, Hofman A, Smith PG: A new variant
of Creutzfeldt-Jakob disease in the UK.  Lancet 1996,
347:921-925.
3. Hill AF, Zeidler M, Ironside J, Collinge J: Diagnosis of new variant
Creutzfeldt-Jakob disease by tonsil biopsy.  Lancet 1997,
349:99-100.
4. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M,
Luthert PJ, Collinge J: Tissue distribution of protease resistant
prion protein in variant Creutzfeldt-Jakob disease using a
highly sensitive immunoblotting assay.  Lancet 2001,
358:171-180.
5. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ: Transmis-
sion of BSE by blood transfusion in sheep.  Lancet 2000,
356:999-1000.
6. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S,
MacKenzie C, Houston F: Transmission of prion diseases by
blood transfusion.  J Gen Virol 2002, 83:2897-2905.
7. 4th case of varient CJD infection associated with blood trans-
fusion  HPA Press Statement 2007 [http://www.hpa.org.uk/hpa/news/
articles/press_releases/2007/070118_vCJD.htm].
8. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J,
Will RG: Possible transmission of variant Creutzfeldt-Jakob
disease by blood transfusion.  Lancet 2004, 363:417-421.
9. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW: Preclinical
vCJD after blood transfusion in a PRNP codon 129 hetero-
zygous patient.  Lancet 2004, 364:527-529.
10. Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan
JM, Brandner S, Wadsworth JD, Hewitt P, Collinge J: Clinical pres-
entation and pre-mortem diagnosis of variant Creutzfeldt-
Jakob disease associated with blood transfusion: a case
report.  Lancet 2006, 368:2061-2067.
11. Clarke P, Ghani AC: Projections of the future course of the pri-
mary vCJD epidemic in the UK: inclusion of subclinical infec-
tion and the possibility of wider genetic susceptibility.  J R Soc
Interface 2005, 2:19-31.
12. Wadsworth JD, Asante EA, Desbruslais M, Linehan JM, Joiner S, Gow-
land I, Welch J, Stone L, Lloyd SE, Hill AF, Brandner S, Collinge J:
Human prion protein with valine 129 prevents expression of
variant CJD phenotype.  Science 2004, 306:1793-1796.
13. Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, Le GM,
Ritchie DL, McCardle LM, Hilton DA: Variant Creutzfeldt-Jakob
disease: prion protein genotype analysis of positive appendix
tissue samples from a retrospective prevalence study.  BMJ
2006, 332:1186-1188.
14. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC,
Drohan WN: The distribution of infectivity in blood compo-
nents and plasma derivatives in experimental models of
transmissible spongiform encephalopathy.  Transfusion 1998,
38:810-816.
15. Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R,
Drohan WN: Further studies of blood infectivity in an experi-
mental model of transmissible spongiform encephalopathy,
with an explanation of why blood components do not trans-
mit Creutzfeldt-Jakob disease in humans.  Transfusion 1999,
39:1169-1178.
16. Haik S, Faucheux BA, Sazdovitch V, Privat N, Kemeny JL, Perret-Liau-
det A, Hauw JJ: The sympathetic nervous system is involved in
variant Creutzfeldt-Jakob disease.  Nat Med 2003, 9:1121-1123.
17. Klein MA, Frigg R, Raeber AJ, Flechsig E, Hegyi I, Zinkernagel RM,
Weissmann C, Aguzzi A: PrP expression in B lymphocytes is not
required for prion neuroinvasion.  Nat Med 1998, 4:1429-1433.
18. Mabbott NA, Bruce ME: The immunobiology of TSE diseases.  J
Gen Virol 2001, 82:2307-2318.
19. Prinz M, Heikenwalder M, Junt T, Schwarz P, Glatzel M, Heppner FL,
Fu YX, Lipp M, Aguzzi A: Positioning of follicular dendritic cells
within the spleen controls prion neuroinvasion.  Nature 2003,
425:957-962.
20. Hunter N: Scrapie and experimental BSE in sheep.  Br Med Bull
2003, 66:171-183.
21. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, Samad S,
Masson S, Bishop M, McCardle L, Ironside JW: Peripheral tissue
involvement in sporadic, iatrogenic, and variant Creutzfeldt-
Jakob disease: an immunohistochemical, quantitative, and
biochemical study.  Am J Pathol 2004, 164:143-153.
22. Bruce ME, McConnell I, Will RG, Ironside JW: Detection of variant
Creutzfeldt-Jakob disease infectivity in extraneural tissues.
Lancet 2001, 358:208-209.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2007, 5:41 http://www.translational-medicine.com/content/5/1/41
Page 9 of 9
(page number not for citation purposes)
23. Castilla J, Saa P, Morales R, Abid K, Maundrell K, Soto C: Protein
misfolding cyclic amplification for diagnosis and prion prop-
agation studies.  Methods Enzymol 2006, 412:3-21.
24. Saa P, Castilla J, Soto C: Ultra-efficient replication of infectious
prions by automated protein misfolding cyclic amplification.
J Biol Chem 2006, 281:35245-35252.
25. Brown P: Blood infectivity, processing and screening tests in
transmissible spongiform encephalopathy.  Vox Sang 2005,
89:63-70.
26. Parveen I, Moorby J, Allison G, Jackman R: The use of non-prion
biomarkers for the diagnosis of Transmissible Spongiform
Encephalopathies in the live animal.  Vet Res 2005, 36:665-683.
27. Lasch P, Schmitt J, Beekes M, Udelhoven T, Eiden M, Fabian H, Petrich
W, Naumann D: Antemortem identification of bovine spongi-
form encephalopathy from serum using infrared spectros-
copy.  Anal Chem 2003, 75:6673-6678.
28. Lasch P, Beekes M, Schmitt J, Naumann D: Detection of preclinical
scrapie from serum by infrared spectroscopy and chemo-
metrics.  Anal Bioanal Chem 2007, 387:1791-1800.
29. Schmitt J, Beekes M, Brauer A, Udelhoven T, Lasch P, Naumann D:
Identification of scrapie infection from blood serum by Fou-
rier transform infrared spectroscopy.  Anal Chem 2002,
74:3865-3868.
30. Stove GC: Radar apparatus for imaging and/or spectrometric
analysis and methods of performing imaging and/or spectro-
metric analysis of a substance for dimensional measure-
ment, identification and precision radar mapping.  2005, 10/
070,768:1-37 [http://patft.uspto.gov/netacgi/
nprser?Sect2=PTO1&Sect2=HIT
OFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearcbool.html&r=1&f=G&l=
50&d=PALL&RefS rch=yes&Query=PN%2F6864826]. Edinburgh, GB
31. Valentine H, Fraser J, Stove GC, Barclay GR, Farquhar CF: Atomic
dielectric resonance spectroscopy: a novel technique for the
identification of TSE infected tissues (Poster in International
Conference on Transmissible Spongiform Encephalopathies,
Edinburgh).: 2002/9; Edinburgh.  2002.
32. Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia
M, Hauw JJ, Ironside JW, Jellinger K, .: Neuropathological diagnos-
tic criteria for Creutzfeldt-Jakob disease (CJD) and other
human spongiform encephalopathies (prion diseases).  Brain
Pathol 1995, 5:459-466.
33. Ironside JW, Head MW, Bell JE, McCardle L, Will RG: Laboratory
diagnosis of variant Creutzfeldt-Jakob disease.  Histopathology
2000, 37:1-9.
34. Beekes M, Lasch P, Naumann D: Analytical applications of Fou-
rier transform-infrared (FT-IR) spectroscopy in microbiol-
ogy and prion research.  Vet Microbiol 2007, 123(4):305-319.